Abstract
Anxiety and depression commonly occur together resulting in worse health outcomes than when they occur in isolation. We aimed to determine whether the genetic liability for combined anxiety and depression was greater than when anxiety or depression occurred alone. Data from 12,558 genotyped twins (ages 38-85) were analysed, including 1,986 complete monozygotic and 1,809 complete dizygotic pairs. Outcomes were prescription of antidepressant and anxiolytic drugs, as demined by the World Health Organization Anatomical Therapeutic Chemical Classimication System (ATC) convention, for combined anxiety and depression (n = 1054), anxiety only (n = 744), and depression only (n = 511). Heritability of each outcome was estimated using twin modelling, and the inmluence of common genetic variation was assessed from polygenic scores (PGS) for depressive symptoms, anxiety, and 40 other traits. Heritability of combined anxiety and depression was 79% compared with 41% for anxiety and 50% for depression alone. The PGS for depressive symptoms likewise predicted more variation in combined anxiety and depression (adjusted odds ratio per SD PGS = 1.53, 95% CI = 1.43-1.63; ΔR2 = .031, ΔAUC = .044) than the other outcomes, with nearly identical results when combined anxiety and depression was demined by International Classimication of Diseases (ICD) diagnoses (adjusted odds ratio per SD PGS = 1.70, 95% CI = 1.53-1.90; ΔR2 = .036, ΔAUC = .051). Individuals in the highest decile of PGS for depressive symptoms had over 5 times higher odds of being prescribed medication for combined anxiety and depression compared to those in the lowest decile. We conclude that genetic factors explain substantially more variation in combined anxiety and depression than anxiety or depression alone.
Competing Interest Statement
Henrik Larsson reports receiving grants from Shire Pharmaceuticals; personal fees from and serving as a speaker for Medice, Shire/Takeda Pharmaceuticals and Evolan Pharma AB; and sponsorship for a conference on attention-deficit/hyperactivity disorder from Shire/Takeda Pharmaceuticals and Evolan Pharma AB, all outside the submitted work. Henrik Larsson is editor-in-chief of JCPP Advances. No other authors report financial interests or potential conflicts of interest.
Funding Statement
This research was supported by grants from the Swedish Research Council (2018-01322) and the Bank of Sweden Tercentenary Foundation (P20-0125). The computations and data handling were enabled by resources provided by the National Academic Infrastructure for Supercomputing in Sweden (NAISS) and the Swedish National Infrastructure for Computing (SNIC) at Uppsala Multidisciplinary Center for Advanced Computational Science (UPPMAX) partially funded by the Swedish Research Council through grant agreements no. 2022-06725 and no. 2018-05973.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Data was provided by the Swedish Twin Registry and they have in turn received approval from The Swedish Ethical Review Authority.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data has been provided by the Swedish Twin Registry and any access needs to be approved and granted by them.
